논문검색
Author Min Hee Hong, M.D.1,2,3, Hyo Song Kim, M.D.1,2,3, Chan Kim, M.D.1,2,3, Jung Ryun Ahn, M.D.1,2,3, Hong Jae Chon, M.D.1,2,3, Sang-Joon Shin, M.D.1,2,3, Joong-Bae Ahn, M.D.1,2,3, Hyun Cheol Chung, M.D., Ph.D.1,2,3, Sun Young Rha, M.D., Ph.D.1,2,3
Place of duty 1Department of Internal Medicine, 2Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 3Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea
Title Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
Publicationinfo Cancer Res Treat 2009 Jun; 041(02): 67-72.
Key_word Renal cell carcinoma, Sunitinib, Korea, Efficacy, Toxicity
Full-Text
Abstract Purpose: The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). Materials and Methods: Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. Results: Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients(18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serumcreatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia(69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-footsyndrome (9.2%). Conclusion: Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
출판정보 대한암학회지 2009 Jun; 041(02): 67-72.